Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 30;18(6):2109364.
doi: 10.1080/21645515.2022.2109364. Epub 2022 Aug 26.

A national platform for Covid-19 vaccine studies recruitment in France: Covireivac volunteer's characteristics

Marion Bonneton  1   2 , Jessica Sambourg  1 , Liem Binh Luong Nguyen  1   3 , Christine Trillou  4 , Joyce Dohou  4 , Olivier Saint Lary  5   6 , Mathieu Schuers  5   7 , Marie Lachâtre  1 , Odile Launay  1   2   3
Affiliations

A national platform for Covid-19 vaccine studies recruitment in France: Covireivac volunteer's characteristics

Marion Bonneton et al. Hum Vaccin Immunother. .

Abstract

During the Covid-19 pandemic, the urgent need for safe and effective vaccines has led to many vaccine trials, implying fast and extensive recruitment of volunteers. In France, until 2020, vaccine clinical research participants were usually recruited locally, through center-based pools of volunteers, and local communication plans. Covireivac is a French public online platform launched on 10/01/2020 that enables national, large-scale recruitment of volunteers for Covid-19 vaccine studies. On the Covireivac website, all adult participants registered online, gave their informed consent, and filled out two online forms with information on their identity, health status (comorbidities, treatments), and known exposure to SARS-CoV-2. Since July 2021, volunteers could mention if their children are interested in participating in a Covid-19 vaccine trial. The objective of this work is to describe Covireivac's volunteer characteristics registered from 10/01/2020 to 11/02/2022. To identify independent volunteer characteristics associated with a period of registration we performed a multivariate logistic regression. Among 54,424 registrations, 52,391 (96%) were analysed; 61% were male (n = 31,893), median age was 50 y; 13% (n = 6586) were healthcare workers. At registration, 15,879 volunteers (33%) reported at least one comorbidity, among whom 16% (n = 7349) were obese and 17% (n = 8346) had hypertension. Most volunteers registered during the first month (n = 35,876, 66%). The Covireivac platform allowed quick and large recruitment of potential volunteers for Covid-19 vaccine trials and could be used on a larger scale for vaccine trials in France. It could facilitate recruitment in vaccine trials and provide sponsors with better visibility of the recruitment capacities of clinical research centers.

Keywords: Covid-19; Vaccine; clinical trial; patient selection.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Covireivac’s volunteer platform registration per week from October 1, 2020 to November 2, 2021.*
Figure 2.
Figure 2.
Age distribution according to gender of Covireivac volunteers (n = 50,399).
See this image and copyright information in PMC

References

    1. Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS.. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:1–7. doi:10.1016/j.ebiom.2016.08.042. - DOI - PMC - PubMed
    1. Verger P, Fressard L, Collange F, Gautier A, Jestin C, Launay O, Raude J, Pulcini C, Peretti-Watel P. Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France. EBioMedicine. 2015;2(8):891–897. doi:10.1016/j.ebiom.2015.06.018. - DOI - PMC - PubMed
    1. Peretti-Watel P, Verger P, Raude J, Constant A, Gautier A, Jestin C, Beck F. Dramatic change in public attitudes towards vaccination during the 2009 influenza A(H1N1) pandemic in France. Eurosurveillance. 2013;18(44):20623. doi:10.2807/1560-7917.ES2013.18.44.20623. - DOI - PubMed
    1. Peretti-Watel P, Seror V, Cortaredona S, Launay O, Raude J, Verger P, Fressard L, Beck F, Legleye S, L’Haridon O. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis. 2020;20(7):769–770. doi:10.1016/S1473-3099(20)30426-6. - DOI - PMC - PubMed
    1. Detoc M, Launay O, Dualé C, Mutter C, Le Huec J-C, Lenzi N, Lucht F, Gagneux-Brunon A, Botelho-Nevers E. Barriers and motivations for participation in preventive vaccine clinical trials: experience of 5 clinical research sites. Vaccine. 2019;37(44):6633–6639. doi:10.1016/j.vaccine.2019.09.048. - DOI - PubMed

Substances